P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales: Usmani, S, Alonso, A, Quach, H, Koh, Y, Guenther, A, Min, CK, Leleu, X, Abdallah, AO, Oriol, A, Bessemer, B, Garg, M, Sandhu, I, Weisel, K, Ocio San Miguel, E, Cavo, M, Zhou, X, Kaisermann, M, Mis, L, Williams, D, Yeakey, A, Ferron-Brady, G, Figueroa, D, Kremer, B, Gupta, I, Janowski, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009797/
http://dx.doi.org/10.1097/01.HS9.0000829628.48136.02
_version_ 1784687341722402816
author Usmani, S
Alonso, A
Quach, H
Koh, Y
Guenther, A
Min, CK
Leleu, X
Abdallah, AO
Oriol, A
Bessemer, B
Garg, M
Sandhu, I
Weisel, K
Ocio San Miguel, E
Cavo, M
Zhou, X
Kaisermann, M
Mis, L
Williams, D
Yeakey, A
Ferron-Brady, G
Figueroa, D
Kremer, B
Gupta, I
Janowski, W
author_facet Usmani, S
Alonso, A
Quach, H
Koh, Y
Guenther, A
Min, CK
Leleu, X
Abdallah, AO
Oriol, A
Bessemer, B
Garg, M
Sandhu, I
Weisel, K
Ocio San Miguel, E
Cavo, M
Zhou, X
Kaisermann, M
Mis, L
Williams, D
Yeakey, A
Ferron-Brady, G
Figueroa, D
Kremer, B
Gupta, I
Janowski, W
author_sort Usmani, S
collection PubMed
description
format Online
Article
Text
id pubmed-9009797
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-90097972022-04-18 P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA Usmani, S Alonso, A Quach, H Koh, Y Guenther, A Min, CK Leleu, X Abdallah, AO Oriol, A Bessemer, B Garg, M Sandhu, I Weisel, K Ocio San Miguel, E Cavo, M Zhou, X Kaisermann, M Mis, L Williams, D Yeakey, A Ferron-Brady, G Figueroa, D Kremer, B Gupta, I Janowski, W Hemasphere Poster Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9009797/ http://dx.doi.org/10.1097/01.HS9.0000829628.48136.02 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Poster
Usmani, S
Alonso, A
Quach, H
Koh, Y
Guenther, A
Min, CK
Leleu, X
Abdallah, AO
Oriol, A
Bessemer, B
Garg, M
Sandhu, I
Weisel, K
Ocio San Miguel, E
Cavo, M
Zhou, X
Kaisermann, M
Mis, L
Williams, D
Yeakey, A
Ferron-Brady, G
Figueroa, D
Kremer, B
Gupta, I
Janowski, W
P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
title P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
title_full P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
title_fullStr P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
title_full_unstemmed P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
title_short P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
title_sort p14: dreamm-9: phase i study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma
topic Poster
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009797/
http://dx.doi.org/10.1097/01.HS9.0000829628.48136.02
work_keys_str_mv AT usmanis p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT alonsoa p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT quachh p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT kohy p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT guenthera p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT minck p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT leleux p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT abdallahao p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT oriola p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT bessemerb p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT gargm p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT sandhui p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT weiselk p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT ociosanmiguele p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT cavom p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT zhoux p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT kaisermannm p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT misl p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT williamsd p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT yeakeya p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT ferronbradyg p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT figueroad p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT kremerb p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT guptai p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma
AT janowskiw p14dreamm9phaseistudyofbelantamabmafodotinplusstandardofcareinpatientswithtransplantineligiblenewlydiagnosedmultiplemyeloma

Ejemplares similares